NY-SOUNDTRAP
6.10.2020 14:02:19 CEST | Business Wire | Press release
Soundtrap today launched Soundtrap Capture , a collaborative mobile app for on-the-go music capture and creation. Built with musicians and artists in mind, the new app is an interactive, user-friendly tool that lets creators collaborate in real time, and record high-quality audio whenever and wherever inspiration strikes. Starting today, Soundtrap Capture is available globally to download for free on the iOS App Store .
“This new app is all about capturing creativity whenever, and wherever it strikes. Whether it’s walking down the street, sitting in a cafe or jamming in the studio - the Soundtrap Capture app lets artists collaborate and create right there in the moment.” - Per Emanuelsson, Director of Soundtrap at Spotify.
Soundtrap empowers high-quality collaborative music-making for people around the world, giving creators the opportunity to jam in one place - see who’s recording, vibe to ideas and discuss and react to them in real time. With the Soundtrap Capture app, turning concepts into songs has never been easier.
Developed in conjunction with artists, Soundtrap Capture is an artist-oriented experience focused on the very first step of the music creation process: the concept. It’s this early stage of the creative process - the first strains of melody, the initial ad-libbed verse, the spontaneous guitar riff - that Soundtrap aims to streamline through Soundtrap Capture.
Based on insights from thousands of musicians and their collaborators, Soundtrap set out to simplify the overly complicated music ideation process, which typically involves many musicians toggling between voice notes, messaging apps, digital audio workstations and storage destinations to get their concepts across. Equipped with built-in tools for recording, layering, real-time collaboration and storage, Soundtrap Capture replaces this multi-platform process with one efficient app.
“Empowering artists to create their best work is core to our mission at Spotify,” said Charlie Hellman, Vice President and Head of Marketplace, Spotify. “I'm excited to see Soundtrap Capture help more musicians simplify the creative process and capture sparks of inspiration.”
With an upcoming update, Soundtrap’s Studio tool will soon allow artists to collaborate seamlessly on projects between the Soundtrap Capture app and the Soundtrap Studio app on mobile or desktop. This zero-friction workflow will enable, for example, a musician to start an idea on the go via Soundtrap Capture, and then have a collaborator pick up and build on that idea using Soundtrap Studio from their computer.
Features immediately available on Soundtrap Capture include:
- Multi-track Layering: layer track recordings, instruments and vocals over one another to create different takes.
- Collaborate with Creators: invite multiple collaborators to join a project, present ideas, record and layer tracks to create songs together in real time.
- Live Storage: immediately sync and back up all projects to the Soundtrap system, and easily access them so that you never lose an idea again.
And coming later this year:
- Seamless Integration: transfer seamlessly between the Soundtrap Capture app and the Soundtrap Studio, between desktop and mobile, all without missing a beat.
ABOUT SOUNDTRAP
A part of Spotify, Soundtrap is the first cloud-based recording platform for music and podcasts that works on all operating systems, enabling people to collaborate and record together wherever they are. With an easy-to-use creation platform, Soundtrap empowers creators to build original content using a combination of software instruments, real instruments and audio recording. For more information, please visit https://www.soundtrap.com .
MEDIA ASSETS
Available for download HERE .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005238/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom